The objective of this study was to evaluate the effects of isotype-specific PI3Kα inhibitors versus alternative pan-PI3K inhibitors or PI3K/mTOR pathway inhibitors in combination with PTX and ICI for treatment of BC. The gene discussed is PIK3CG; the disease is breast cancer.